Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2009

Canadian Center for Cancer Research Receives $8.9M

Canadian Center for Cancer Research Receives $8.9M

Ottawa grant goes to oncolytic research

  • The Ontario Institute for Cancer Research awarded a four-year, C$10 million ($8.9 million) grant to the Centre for Cancer Therapeutics at Ottawa Hospital Research Institute (OHRI). A major portion of this money will fund work in the lab of John Bell, Ph.D., Jennerex' chief collaborator for oncolytic viral therapeutics.

    Jennerex' products are in Phase I and II testing and have reportedly shown positive safety and efficacy results. They are targeted at various solid tumors. Furtherst along is JX-594 for liver cancer. The Mulcahy Manufacturing Unit at OHRI, Ontario's first GMP facility dedicated to oncolytic virus production, is undertaking manufacturing for Jennerex.

    Jennerex oncolytic virus products are genetically modified vaccine viruses designed to target and destroy only cancer cells while ignoring healthy cells.ADNFCR-2184-ID-19216543-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »